Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos    GLPG   BE0003818359

GALAPAGOS (GLPG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/15 05:39:49 pm
77.69 EUR   +8.93%
12/15 GALAPAGOS : to enter NASDAQ Biotech Index
12/15 GALAPAGOS : Transparency notification
12/14 GALAPAGOS : exercises co-promotion option for filgotinib with collab..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
76.04(c) 73.75(c) 72.71(c) 71.32(c) 77.69(c) Last
543 425 603 562 379 633 417 905 1 505 291 Volume
+3.54% -3.01% -1.41% -1.91% +8.93% Change
More quotes
Financials (€)
Sales 2017 123 M
EBIT 2017 -102 M
Net income 2017 48,0 M
Finance 2017 1 183 M
Yield 2017 -
Sales 2018 163 M
EBIT 2018 -83,2 M
Net income 2018 -6,40 M
Finance 2018 1 092 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 22,5x
EV / Sales2018 17,5x
Capitalization 3 957 M
More Financials
Company
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies.It operates through the Research and Development and Fee-for-service segments.The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June... 
More about the company
Surperformance© ratings of Galapagos
Trading Rating : Investor Rating :
More Ratings
Latest news on GALAPAGOS
12/15 GILEAD SCIENCES : Galapagos exercises co-promotion option for filgotinib with co..
12/15 GALAPAGOS : to enter NASDAQ Biotech Index
12/15 GALAPAGOS : Transparency notification
12/14 GALAPAGOS : exercises co-promotion option for filgotinib with collaboration part..
12/11 GALAPAGOS : Transparency notification
12/11 GALAPAGOS : to enter NASDAQ Biotech Index
11/27 ABBVIE : Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
11/27 GALAPAGOS : increases share capital through warrant exercises
11/23 GALAPAGOS : increases share capital through warrant exercises
11/23 ABBVIE : Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
More news
Sector news : Biotechnology & Medical Research - NEC
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15DJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/15 PREMARKET GAINERS AS OF 9 : 05 am
12/15 Galapagos up 9% premarket on decision to co-promote filgotinib in Europe
12/14 Galapagos elects to co-promote filgotinib with Gilead in Europe
12/12 YOUR DAILY PHARMA SCOOP : Gilead Remains Long-Term Story, Argenx Rallies, Bluebi..
12/11 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
Chart GALAPAGOS
Duration : Period :
Galapagos Technical Analysis Chart | GLPG | BE0003818359 | 4-Traders
Technical analysis trends GALAPAGOS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 97,0 €
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS17.03%4 649
CELLTRION, INC.--.--%23 756
IQVIA HOLDINGS INC34.41%21 227
INCYTE CORPORATION-2.16%20 346
LONZA GROUP62.09%19 523
ALNYLAM PHARMACEUTICALS, INC.233.49%12 349